Literature DB >> 17176621

Safety profile of proton pump inhibitors according to the spontaneous reports of suspected adverse reactions.

E Salgueiro1, T Rubio, A Hidalgo, G Manso.   

Abstract

OBJECTIVE: [corrected] To evaluate similarities and differences in safety among proton pump inhibitors (PPIs) under the usual conditions of prescription.
METHODS: A search of spontaneous reports on adverse reactions associated with these drugs and registered between January 1, 2004 and December 31, 2004 was undertaken in the Spanish Pharmacovigilance System Database. We compared the frequency of reports with the consumption of PPIs, and analyzed the organ and system distribution for each PPI. Of the organ and system groups more commonly affected, diarrhea, myalgia, abnormal vision and hepatitis were selected for further analysis.
RESULTS: Nearly 8 times more reports for omeprazole compared to other drugs were found but a similar difference was observed in their consumption. Skin and appendage disorders were more frequently reported for omeprazole and rabeprazole, the urinary, female reproductive and endocrine systems for lansoprazole, musculoskeletal for omeprazole and esomeprazole, vision for pantoprazole, rabeprazole and esomeprazole, gastrointestinal tract for omeprazole and lansoprazole and liver and biliary systems for omeprazole, lansoprazole and pantoprazole. Myalgia appears more often in younger patients than diarrhea, abnormal vision or hepatitis and shows longer periods of latency and recovery. The four adverse reactions analyzed were mainly reversible.
CONCLUSION: A direct relationship was found between consumption and the number of reports. Some organ and system groups were affected by more than one PPI and this showed a specific pattern of group toxicity to these pharmacological agents. Some reports involved only lansoprazole and these require further analysis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17176621     DOI: 10.5414/cpp44548

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  6 in total

Review 1.  The relationship between long-term proton pump inhibitor therapy and skeletal frailty.

Authors:  Arthur N Lau; Michael Tomizza; Matthew Wong-Pack; Alexandra Papaioannou; Jonathan D Adachi
Journal:  Endocrine       Date:  2015-05-07       Impact factor: 3.633

2.  Acid peptic diseases: pharmacological approach to treatment.

Authors:  Alex Mejia; Walter K Kraft
Journal:  Expert Rev Clin Pharmacol       Date:  2009-05       Impact factor: 5.045

3.  Inappropriate Use of Intravenous PPI for Stress Ulcer Prophylaxis in an Inner City Community Hospital.

Authors:  Muhammad K Perwaiz; Gerald Posner; Fadi Hammoudeh; Frances Schmidt; Narayan Neupane; Danilo Enriquez; Neerja Gulati
Journal:  J Clin Med Res       Date:  2010-10-11

Review 4.  The role of the pharmacist in the selection and use of over-the-counter proton-pump inhibitors.

Authors:  Helen F Boardman; Gordon Heeley
Journal:  Int J Clin Pharm       Date:  2015-06-23

Review 5.  Proton Pump Inhibitors and Fractures in Adults: A Critical Appraisal and Review of the Literature.

Authors:  Silvia Irina Briganti; Anda Mihaela Naciu; Gaia Tabacco; Roberto Cesareo; Nicola Napoli; Pierpaolo Trimboli; Marco Castellana; Silvia Manfrini; Andrea Palermo
Journal:  Int J Endocrinol       Date:  2021-01-15       Impact factor: 3.257

Review 6.  Proton Pump Inhibitors and Bone Health: An Update Narrative Review.

Authors:  Eric Lespessailles; Hechmi Toumi
Journal:  Int J Mol Sci       Date:  2022-09-14       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.